Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Updated recommendation by Touchstone Innovations

18 Oct 2017 09:38

RNS Number : 9375T
Touchstone Innovations PLC
18 October 2017
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

 

 

18 October 2017

 

Touchstone Innovations plc

 

Updated recommendation by Touchstone Innovations plc regarding IP Group plc offer (the "Offer")

Further to the announcements by IP Group plc ("IP Group"), the Board of Touchstone Innovations plc ("Touchstone" or the "Company") notes that the CMA clearance condition to the Offer has been fulfilled and that the Offer has been declared wholly unconditional as of this morning.

The Board of Touchstone also notes that IP Group has received valid acceptances in respect of 155,859,312 Touchstone shares, representing approximately 96.6844 per cent of the existing issued share capital of Touchstone, and IP Group's stated intention to commence the procedure pursuant to Chapter 3 of Part 28 of the Companies Act 2006 to compulsorily acquire the remaining Touchstone shares in respect of which the Offer is not accepted on the same terms as the Offer.

Given that the Offer is now wholly unconditional, the Board of Touchstone recommends that Touchstone shareholders who have not yet accepted the Offer now do so promptly.

Those Touchstone shareholders who accept the Offer will receive their new shares in IP Group as consideration for their Touchstone shares at an earlier date than they would as part of the compulsory acquisition procedure referred to above.

The procedure for acceptance of the IP Group Offer is set out in the IP Group offer document dated 18 July 2017, the "Update on Offer for Touchstone Innovations plc" announcement dated 18 September 2017 as well as the "Offer update - Wholly unconditional" announcement dated 18 October 2017.

IP Group has announced that the Offer will remain open until further notice and that not less than 14 calendar days' notice will be given in respect of the closure of the Offer.

The directors of Touchstone who own shares in Touchstone in their personal capacity have decided to accept the Offer in respect of their own beneficial holdings.

If you are a Touchstone shareholder and in any doubt as to the action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, solicitor, accountant, fund manager or other appropriate independent financial adviser authorised under the Financial Services and Markets Act 2000, as amended if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

 

*****

 

Enquiries:

 

Touchstone Innovations plc

020 3053 8834

Russ Cummings

J.P. Morgan Cazenove (Financial Adviser and Corporate Broker to Touchstone Innovations plc)

020 7742 4000

Michael Wentworth-Stanley/ James Robinson/ Alec Pratt

RBC Capital Markets

(Joint Corporate Broker to Touchstone Innovations plc)

020 7653 4000

Marcus Jackson

Instinctif Partners

020 7457 2020

Adrian Duffield/Melanie Toyne-Sewell/Chantal Woolcock

 

 

Further Information

 

J.P. Morgan Limited, which conducts its UK investment banking business as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"), is authorised and regulated in the United Kingdom by the Financial Conduct Authority. J.P. Morgan Cazenove is acting as financial adviser exclusively for Touchstone Innovations plc and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Touchstone Innovations plc for providing the protections afforded to clients of J.P. Morgan Cazenove or its affiliates, or for providing advice in relation to any matter referred to herein.

RBC Capital Markets is the business name used by RBC Europe Limited, which is authorised in the United Kingdom by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA and is a subsidiary of the Royal Bank of Canada. RBC is acting as Corporate Broker to the Company.

Responsibility

The directors of Touchstone accept responsibility for the information contained in this announcement (including expressions of belief) and, to the best of the knowledge and belief of the Touchstone directors (having taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Additional Information

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at www.touchstoneinnovations.com by no later than 12 noon (London time) on the business day following this announcement. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

Ends

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPVVLBFDBFXFBE
Date   Source Headline
5th Sep 20162:40 pmRNSHolding(s) in Company
24th Aug 20167:01 amRNSCell Medica and UCL collaboration
12th Jul 20167:02 amRNSCell Medica acquires Delenex Therapeutics
6th Jul 20167:00 amRNSEconic raises £5m to develop novel catalyst tech
30th Jun 201612:11 pmRNSPsiOxus and Bristol-Myers Squibb collaboration
28th Jun 20167:00 amRNSStorm Therapeutics raises £12m
21st Jun 20164:35 pmRNSPrice Monitoring Extension
21st Jun 20167:00 amRNSDirector's share purchase
20th Jun 20167:03 amRNSCircassia cat allergy Phase III study
17th Jun 20167:00 amRNSCell Medica and Baylor College of Medicine partner
16th Jun 201610:44 amRNSReplacement Holding(s) in Company
14th Jun 20163:20 pmRNSEdison issues outlook on Imperial Innovations)
14th Jun 20169:00 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAllotment of Deferred Placing Shares
31st May 20167:00 amRNSFeaturespace closes £6.2 million funding round
26th May 20167:00 amRNS£3 million funding round for Inflowmatix
11th May 201612:32 pmRNSDavid Newlands appointed Chairman
4th May 20164:35 pmRNSPrice Monitoring Extension
4th May 201611:08 amRNSNexeon raises £30m, plans development lab in Asia
4th May 20167:00 amRNSAnalyst and Investor day
29th Apr 20164:35 pmRNSPrice Monitoring Extension
29th Apr 201612:42 pmRNSSale of Innovations portfolio Stanmore Implants
7th Apr 20167:00 amRNSHalf Yearly Report
21st Mar 20167:00 amRNSDr Martin Knight to step down from the board
18th Mar 201612:40 pmRNSNotice of Results
17th Mar 20167:00 amRNSTopiVert reports successful Phase I clinical study
26th Feb 20168:39 amRNSHolding(s) in Company
25th Feb 20163:59 pmRNSHolding(s) in Company
25th Feb 20163:50 pmRNSHolding(s) in Company
25th Feb 20168:53 amRNSHolding(s) in Company
22nd Feb 20165:01 pmRNSAdmission of shares to trading on AIM
22nd Feb 201612:29 pmRNSResult of General Meeting
22nd Feb 20167:00 amRNS£13.5m funding round in Precision Ocular
11th Feb 20162:51 pmRNSHolding(s) in Company
8th Feb 20167:00 amRNSInnovations leads £5m Series A round in Aqdot
4th Feb 20166:08 pmRNSResult of Placing
4th Feb 20167:00 amRNSPlacing to raise £100 million
2nd Feb 20167:00 amRNSMISSION Therapeutics raises £60 million
26th Jan 20167:00 amRNSInivata completes £31.5m Series A funding round
25th Jan 20167:00 amRNSInnovations joins Apollo consortium
18th Jan 20167:00 amRNSInnovations invests £25m in new £50m UCL Tech Fund
2nd Dec 20157:00 amRNSKesios Therapeutics raises £19 million
19th Nov 20151:51 pmRNSResult of AGM
4th Nov 20151:40 pmRNSGrant of share options
28th Oct 20157:00 amRNSPosting of Annual Report and Notice of AGM
22nd Oct 20157:00 amRNSLeads £1.5m seed funding into AI pioneer, Telectic
14th Oct 20157:00 amRNSFinal Results
22nd Sep 20154:10 pmRNSNotice of Results
12th Aug 20157:00 amRNSIssue of Equity
4th Aug 20157:01 amRNS£2.5m funding round in Oxford Biotrans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.